2411 Stanwell Drive
336 articles with Cerus Corporation
Cerus Corporation (Nasdaq:CERS) announced today that its fourth quarter and full-year 2018 results will be released on Tuesday, February 26, 2019, after the close of the stock market.
2019 product revenue guidance of $70 million to $73 million, representing growth of 15% to 20% over preliminary 2018 results
Cerus Corporation (Nasdaq:CERS) today announced the initiation and first patient enrollment in ReCePI, a randomized, double-blinded, controlled, parallel group, non-inferiority, Phase 3 study to evaluate the efficacy and safety of the INTERCEPT Blood System for red blood cells in patients undergoing complex cardiac surgery procedures.
Cerus today announced that it has filed for CE Mark registration for the Company’s INTERCEPT red blood cell system.
Cerus Corporation (Nasdaq:CERS) announced today the issuance of a new U.S. Food and Drug Administration (FDA) draft guidance document on bacterial risk control strategies for platelet collection and transfusion.
Cerus Corporation (Nasdaq:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Vivek Jayaraman, Cerus’ chief commercial officer, are scheduled to present a corporate update at the 2018 Canaccord Genuity Medical Technologies and Diagnostics Forum at 1:30 p.m. ET on Thursday, November 15, 2018.
Cerus Corporation (Nasdaq:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin Green, Cerus’ vice president, finance and chief financial officer, are scheduled to present a corporate update at the 2018 Stephens NY Investment Conference
Cerus Corporation announced today financial results for the third quarter ended September 30, 2018.
The basis of the designation is improved treatment of massive hemorrhage, a life-threatening medical condition.
Cerus Corporation (Nasdaq:CERS) announced today that its third quarter results will be released on Thursday, November 1, 2018, after the close of the stock market.
Cerus to Provide Update to Development Programs and Outline Growth Strategy at 2018 Institutional Investor Meeting
Cerus Corporation (Nasdaq: CERS) is presenting its strategic roadmap and outlining its multi-year growth strategy at the 2018 Cerus Institutional Investor Meeting today in Boston.
Company’s co-founder and chief scientific officer has been awarded the prestigious Dale A. Smith Memorial Award by AABB’s National Blood Foundation.
Cerus Corporation today announced the appointment of Eric Bjerkholt to its Board of Directors.
Institutional Investor Meeting on Tuesday, October 16, 2018 in Boston, Massachusetts.
Cerus’ president and chief executive officer will present and provide a corporate update at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York City on Tuesday, October 2, 2018 at 3:25 p.m. ET.
Product revenue increases 62% compared to 2017
Cerus Corporation announced today that its second quarter results will be released on Thursday, August 2, 2018, after the close of the stock market.
Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association
Cerus Corporation announced that results from SPARC were presented today at the 23rd Congress of European Hematology Association.
Cerus Announces Presentations Highlighting INTERCEPT Blood Systems at the 35th International Congress of the International Society of Blood Transfusion
Cerus Corporation announced that it will make multiple presentations, including two oral abstracts, that will be featured at the 35th International Congress of the International Society of Blood Transfusion (ISBT).
Cerus Corporation announced that Dr. Laurence M. Corash, co-founder and chief scientific officer, and Lainie Corten, vice president of global marketing, are scheduled to present a corporate update at the Deutsche Bank 43rd Annual Health Care Conference.